slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 21,811-21,840
Pages 885
Rows per page 30
Arc
21,811-21,840 of 26,550
14
Data presented at EASL 2022. Shows correlation between T-cell activation and HBsAg reduction.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
15
The slide uses a bulleted list to present key safety outcomes, including lack of serious adverse events and specific laboratory findings.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
16
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
04
Uses a comparative structure to contrast Sepsis vs Septic Shock, followed by impact metrics.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
Uses a before-after-bridge framework to contrast current pain points with the proposed solution.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
The slide uses a two-column layout to contrast the hardware platform with the consumable cartridges.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
06
Includes a Kaplan-Meier survival curve, an anatomical illustration of tumor locations, and a comparative table of clinical outcomes.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
BICR = Blinded Independent Central Review; RANO = Response Assessment in Neuro-Oncology; HGG = High-Grade Glioma; LGG = Low-Grade Glioma; SAEs = Serious Adverse Events.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
08
The slide details specific inclusion/exclusion criteria, including age, mutation status, prior therapy, and washout periods.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
09
The slide highlights clinical trial results with specific response and disease control rates for two different RANO criteria.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
10
The chart is a waterfall plot (often called a swimmer plot or spider plot in oncology, though technically a waterfall).Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
11
The chart is a waterfall plot showing Best % Change in SPD from Baseline. The legend indicates PS scores (060-100).Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
12
The chart is a classic 'spider plot' used in oncology clinical trials to visualize individual patient tumor burden changes over time.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
13
Data presented in two tables comparing healthy adult dose escalation vs glioma patient safety profiles.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
14
The slide highlights the correlation between RANO response criteria and improved clinical outcomes in H3 K27M-mutant DMG patients.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
15
The table uses a color-coded heatmap to highlight favorable (green) vs unfavorable (pink) characteristics of clinical trial data.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
16
Chimerix | Investor Presentation Deck | 43 slidesChimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
17
The slide uses a process flow diagram to illustrate the trial structure.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
18
Chimerix | Investor Presentation Deck | 43 slidesChimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
19
The slide details specific event counts and target hazard ratios for OS and PFS endpoints.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
20
The chart shows a dose-response curve where longer incubation times (48+ hours) result in higher efficacy (lower cell viability) at lower concentrations compared to 24 hours.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
21
Chimerix | Investor Presentation Deck | 43 slidesChimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
22
The slide uses a medical illustration of the brain to map patient counts and positivity rates to specific anatomical regions.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
23
Chimerix | Investor Presentation Deck | 43 slidesChimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
24
Slide 24 of the deck.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
25
Waterfall plot displays individual patient responses; PD indicates Progressive Disease threshold.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
26
Chimerix | Investor Presentation Deck | 43 slidesChimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
27
Includes a detailed biological pathway diagram showing mitochondrial and membrane-level interactions.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
28
Includes citations to Chi et al. (2017) and Piccardo et al. (2019).Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
29
Includes a mechanism illustration, a bar chart of H3K27me3 levels, a Kaplan-Meier survival curve, and a dot plot of patient tumor data.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit